Robert E. Landry - 12 Jan 2024 Form 4 Insider Report for REGENERON PHARMACEUTICALS, INC. (REGN)

Role: EVP Finance CFO
Signature: /s/**Robert E. Landry
Issuer symbol: REGN
Transactions as of: 12 Jan 2024
Net transactions value: -$224,022
Form type: 4
Filing time: 17 Jan 2024, 16:03:43 UTC
Previous filing: 08 Jan 2024
Next filing: 18 Jan 2024
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	REGN	Common Stock	Options Exercise	$303,184	+800	+3.5%	$378.98	23,406	12 Jan 2024	Direct
transaction	REGN	Common Stock	Tax liability	$527,206	-568	-2.4%	$928.18	22,838	12 Jan 2024	Direct
holding	REGN	Common Stock						270	12 Jan 2024	By 401(k) Plan

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	REGN	Non-Qualified Stock Option (right to buy)	Options Exercise	$0	-800	-5.2%	$0.000000	14,687	12 Jan 2024	Common Stock	800	$378.98	Direct	F1

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The stock option award vests in four equal annual installments, commencing one year after the date of grant.